Daryl Tan-Yeung Lau, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B, Chronic | 27 | 2022 | 345 | 5.210 |
Why?
|
| Hepatitis B virus | 28 | 2022 | 460 | 4.220 |
Why?
|
| Hepatitis B | 11 | 2022 | 650 | 2.240 |
Why?
|
| Hepatitis B Surface Antigens | 8 | 2022 | 293 | 2.120 |
Why?
|
| Hepatitis B e Antigens | 11 | 2021 | 105 | 1.890 |
Why?
|
| Hepatitis B Core Antigens | 4 | 2021 | 83 | 1.460 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2022 | 2091 | 1.410 |
Why?
|
| Hepatitis C, Chronic | 9 | 2022 | 1005 | 1.240 |
Why?
|
| Antiviral Agents | 25 | 2022 | 2802 | 1.190 |
Why?
|
| Liver Neoplasms | 10 | 2022 | 4103 | 1.100 |
Why?
|
| DNA, Viral | 15 | 2021 | 2285 | 0.930 |
Why?
|
| Hepatitis B Antibodies | 3 | 2022 | 151 | 0.900 |
Why?
|
| Cryoglobulinemia | 1 | 2022 | 86 | 0.870 |
Why?
|
| Hepatitis C | 7 | 2022 | 1521 | 0.830 |
Why?
|
| Hepacivirus | 11 | 2022 | 1322 | 0.740 |
Why?
|
| Virus Activation | 2 | 2018 | 329 | 0.710 |
Why?
|
| Interferon-alpha | 6 | 2014 | 899 | 0.700 |
Why?
|
| Superinfection | 1 | 2018 | 58 | 0.670 |
Why?
|
| Liver Cirrhosis | 9 | 2022 | 1757 | 0.670 |
Why?
|
| Hepatitis E | 1 | 2018 | 72 | 0.630 |
Why?
|
| Alanine Transaminase | 10 | 2021 | 602 | 0.610 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2022 | 703 | 0.590 |
Why?
|
| Kupffer Cells | 2 | 2013 | 158 | 0.560 |
Why?
|
| Liver | 10 | 2020 | 7594 | 0.550 |
Why?
|
| RNA, Viral | 4 | 2021 | 2838 | 0.400 |
Why?
|
| Interferons | 5 | 2019 | 678 | 0.390 |
Why?
|
| Interferon Regulatory Factor-3 | 2 | 2008 | 120 | 0.390 |
Why?
|
| Aspartate Aminotransferases | 4 | 2015 | 415 | 0.300 |
Why?
|
| Hepatitis A Antibodies | 1 | 2005 | 17 | 0.290 |
Why?
|
| Viral Load | 7 | 2019 | 3254 | 0.270 |
Why?
|
| Platelet Count | 3 | 2015 | 795 | 0.240 |
Why?
|
| North America | 3 | 2021 | 1202 | 0.240 |
Why?
|
| Immune Tolerance | 1 | 2012 | 2313 | 0.240 |
Why?
|
| Genotype | 8 | 2021 | 12919 | 0.240 |
Why?
|
| Immunity, Innate | 2 | 2012 | 2943 | 0.230 |
Why?
|
| Cryoglobulins | 1 | 2022 | 62 | 0.230 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2009 | 241 | 0.220 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2020 | 23 | 0.210 |
Why?
|
| alpha-Fetoproteins | 1 | 2022 | 221 | 0.210 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1833 | 0.190 |
Why?
|
| Biopsy | 7 | 2020 | 6736 | 0.190 |
Why?
|
| Adenine | 1 | 2004 | 897 | 0.180 |
Why?
|
| Liver Function Tests | 3 | 2019 | 534 | 0.180 |
Why?
|
| Liver Diseases | 2 | 2013 | 1243 | 0.170 |
Why?
|
| Humans | 59 | 2022 | 715777 | 0.170 |
Why?
|
| Virus Replication | 6 | 2022 | 2565 | 0.170 |
Why?
|
| Hepatitis B Vaccines | 1 | 2019 | 193 | 0.160 |
Why?
|
| Actins | 1 | 2005 | 2167 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2019 | 329 | 0.160 |
Why?
|
| Adult | 29 | 2022 | 212266 | 0.150 |
Why?
|
| Liver Failure, Acute | 1 | 2018 | 175 | 0.150 |
Why?
|
| Female | 35 | 2022 | 377204 | 0.150 |
Why?
|
| Viremia | 1 | 2019 | 722 | 0.150 |
Why?
|
| Lymphocyte Activation | 2 | 2019 | 5853 | 0.140 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 12305 | 0.140 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 2939 | 0.140 |
Why?
|
| Genetic Variation | 4 | 2021 | 6664 | 0.140 |
Why?
|
| Lamivudine | 3 | 2007 | 336 | 0.140 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2018 | 2034 | 0.140 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 1177 | 0.140 |
Why?
|
| Guanine | 1 | 2016 | 281 | 0.130 |
Why?
|
| Fatigue | 1 | 2022 | 1453 | 0.130 |
Why?
|
| Electricity | 1 | 2015 | 176 | 0.130 |
Why?
|
| Microtechnology | 1 | 2014 | 73 | 0.130 |
Why?
|
| Hepatitis B Antigens | 1 | 2013 | 41 | 0.130 |
Why?
|
| Gastroenterology | 1 | 2020 | 513 | 0.120 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2015 | 203 | 0.120 |
Why?
|
| Puerperal Disorders | 1 | 2016 | 282 | 0.120 |
Why?
|
| STAT Transcription Factors | 1 | 2014 | 177 | 0.120 |
Why?
|
| Hepatocytes | 2 | 2012 | 1238 | 0.120 |
Why?
|
| Janus Kinases | 1 | 2014 | 226 | 0.120 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 10284 | 0.120 |
Why?
|
| Middle Aged | 22 | 2021 | 214639 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2008 | 9504 | 0.110 |
Why?
|
| Male | 29 | 2022 | 350324 | 0.110 |
Why?
|
| Host-Pathogen Interactions | 2 | 2018 | 1489 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2019 | 1323 | 0.100 |
Why?
|
| Lectins | 1 | 2013 | 560 | 0.100 |
Why?
|
| Recombinant Proteins | 4 | 2014 | 6803 | 0.100 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 277 | 0.100 |
Why?
|
| Prediabetic State | 1 | 2015 | 467 | 0.100 |
Why?
|
| Nanostructures | 1 | 2015 | 567 | 0.090 |
Why?
|
| Hepatitis C Antigens | 1 | 2009 | 35 | 0.090 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 964 | 0.090 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 613 | 0.090 |
Why?
|
| Algorithms | 4 | 2021 | 13758 | 0.090 |
Why?
|
| Interferon Type I | 1 | 2012 | 501 | 0.090 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 13643 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 4919 | 0.090 |
Why?
|
| Age Factors | 3 | 2022 | 18784 | 0.090 |
Why?
|
| Viral Core Proteins | 1 | 2009 | 168 | 0.090 |
Why?
|
| Receptors, Virus | 1 | 2012 | 671 | 0.090 |
Why?
|
| Nanotechnology | 1 | 2014 | 697 | 0.090 |
Why?
|
| Serologic Tests | 2 | 2022 | 381 | 0.090 |
Why?
|
| Inflammasomes | 1 | 2013 | 444 | 0.090 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 486 | 0.080 |
Why?
|
| Quantum Dots | 1 | 2009 | 171 | 0.080 |
Why?
|
| Young Adult | 7 | 2021 | 56226 | 0.080 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2009 | 270 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 962 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 11689 | 0.080 |
Why?
|
| Mass Screening | 1 | 2003 | 5209 | 0.080 |
Why?
|
| Hepatitis, Chronic | 1 | 2006 | 51 | 0.080 |
Why?
|
| Hepatitis A virus | 1 | 2005 | 13 | 0.070 |
Why?
|
| Drug Resistance, Viral | 2 | 2011 | 780 | 0.070 |
Why?
|
| Aged | 9 | 2021 | 162448 | 0.070 |
Why?
|
| Prospective Studies | 6 | 2021 | 51315 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 39300 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2004 | 602 | 0.060 |
Why?
|
| Chromatography | 1 | 2003 | 211 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 58323 | 0.060 |
Why?
|
| Incidence | 4 | 2022 | 20731 | 0.060 |
Why?
|
| Models, Theoretical | 2 | 2012 | 3580 | 0.060 |
Why?
|
| Pregnancy | 3 | 2019 | 27398 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2015 | 19910 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2008 | 718 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 1824 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 635 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 4492 | 0.050 |
Why?
|
| Canada | 2 | 2019 | 1967 | 0.050 |
Why?
|
| United States | 8 | 2021 | 67905 | 0.050 |
Why?
|
| Adolescent | 5 | 2021 | 85155 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2021 | 41198 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2013 | 2256 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 3947 | 0.050 |
Why?
|
| ROC Curve | 3 | 2020 | 3524 | 0.050 |
Why?
|
| Ontario | 1 | 2021 | 366 | 0.050 |
Why?
|
| Retrospective Studies | 6 | 2018 | 72443 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2013 | 5102 | 0.040 |
Why?
|
| Phenotype | 4 | 2019 | 16311 | 0.040 |
Why?
|
| Child | 3 | 2022 | 74468 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 14902 | 0.040 |
Why?
|
| Population Groups | 1 | 2019 | 200 | 0.040 |
Why?
|
| Neutropenia | 1 | 2003 | 876 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2019 | 375 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 6552 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5463 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 3844 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2018 | 9030 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2008 | 2699 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 29291 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 4040 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2020 | 1695 | 0.040 |
Why?
|
| Carrier State | 1 | 2019 | 538 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 2973 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2020 | 21797 | 0.030 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2014 | 9 | 0.030 |
Why?
|
| Transaminases | 1 | 2015 | 209 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2003 | 1328 | 0.030 |
Why?
|
| Orthomyxoviridae | 1 | 2015 | 146 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 250 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 696 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2019 | 40029 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 23438 | 0.030 |
Why?
|
| Alaska | 1 | 2013 | 61 | 0.030 |
Why?
|
| Time Factors | 3 | 2018 | 40875 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 15199 | 0.030 |
Why?
|
| Disease Progression | 2 | 2022 | 13215 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 15909 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2014 | 180 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 322 | 0.030 |
Why?
|
| Publishing | 1 | 2020 | 805 | 0.030 |
Why?
|
| Caspase 1 | 1 | 2013 | 218 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2013 | 756 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1900 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2015 | 517 | 0.030 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 16736 | 0.030 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2013 | 175 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2018 | 990 | 0.030 |
Why?
|
| RNA | 1 | 2021 | 2613 | 0.030 |
Why?
|
| Cell Line | 2 | 2019 | 16576 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2015 | 587 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 3722 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2014 | 435 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2007 | 8075 | 0.030 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2014 | 387 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 4893 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 2599 | 0.020 |
Why?
|
| Endopeptidases | 1 | 2014 | 779 | 0.020 |
Why?
|
| Proteins | 1 | 2005 | 6070 | 0.020 |
Why?
|
| DNA Primers | 2 | 2005 | 2979 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2015 | 1203 | 0.020 |
Why?
|
| Microfluidics | 1 | 2015 | 625 | 0.020 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2013 | 553 | 0.020 |
Why?
|
| Environment | 1 | 2015 | 1097 | 0.020 |
Why?
|
| Temperature | 1 | 2015 | 2145 | 0.020 |
Why?
|
| Chemokines | 1 | 2013 | 962 | 0.020 |
Why?
|
| Prevalence | 2 | 2015 | 14911 | 0.020 |
Why?
|
| RNA, Double-Stranded | 1 | 2009 | 271 | 0.020 |
Why?
|
| Survivors | 1 | 1998 | 2171 | 0.020 |
Why?
|
| Linear Models | 1 | 2018 | 5983 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 2244 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 1684 | 0.020 |
Why?
|
| Prognosis | 2 | 2022 | 29005 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2013 | 1581 | 0.020 |
Why?
|
| Replicon | 1 | 2006 | 37 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 3250 | 0.020 |
Why?
|
| Equipment Design | 1 | 2015 | 3588 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 3818 | 0.020 |
Why?
|
| Recurrence | 1 | 2018 | 8240 | 0.020 |
Why?
|
| Vaccination | 1 | 2018 | 2939 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2014 | 1704 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 6655 | 0.020 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2005 | 138 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2007 | 611 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2013 | 13213 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 19537 | 0.010 |
Why?
|
| Base Sequence | 2 | 2005 | 13179 | 0.010 |
Why?
|
| Computer Systems | 1 | 2004 | 479 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 13217 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12480 | 0.010 |
Why?
|
| Developing Countries | 1 | 2014 | 2737 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 3045 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2006 | 1687 | 0.010 |
Why?
|
| Public Health | 1 | 2014 | 2430 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 3713 | 0.010 |
Why?
|
| Infant | 2 | 2019 | 34569 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13618 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2015 | 6259 | 0.010 |
Why?
|
| Gene Expression | 1 | 2014 | 7954 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2015 | 62004 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2014 | 23729 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2015 | 10620 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 15603 | 0.010 |
Why?
|
| Cytokines | 1 | 2013 | 7190 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20356 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 6089 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 3529 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 6274 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 34430 | 0.010 |
Why?
|
| Mitochondria | 1 | 2006 | 3613 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 7960 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 7446 | 0.010 |
Why?
|